Annual Primary CNS Lymphoma Collaborative Group Meeting

年度原发性中枢神经系统淋巴瘤合作小组会议

• 批准号: 7908725
• 负责人: Tracy T Batchelor
• 金额: $ 0.5万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-01 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7908725
• 关键词: Biological; Central Nervous System Lymphoma; Clinical Investigator; Clinical Sciences; Clinical Trials; Collaborations; Consensus; Diagnosis; Discipline; Fostering; Goals; Group Meetings; Guidelines; International; Lymphoma; Methods; Nervous system structure; Patients; Peer Review; Physicians; Publications; Publishing; Research; Research Personnel; Scientist; Series; Switzerland; T-Cell Lymphoma; Vision; base; clinical care; medical specialties; meetings; multidisciplinary; neurotoxicity; patient population; pre-clinical; prospective; symposium

DESCRIPTION (provided by applicant): The International Primary CNS Lymphoma Collaborative Group (IPCG), formed at the 8th International Conference on Malignant Lymphomas in Lugano, Switzerland in June 2002, meets on a biannual basis and has attracted both a multidisciplinary and international membership. The primary objective of the IPCG is to advance the biological understanding, diagnosis and treatment of patients with primary central nervous system lymphoma (PCNSL). Topics of prior meetings have included: 1) Consensus guidelines for PCNSL clinical trials; 2) Primary T-cell lymphoma of the nervous system; 3) Low-grade CNS lymphoma. The goals of each thematic meeting are to review the preclinical and clinical science relevant to each topic; to produce multidisciplinary, collaborative research focused on each selected topic and, when appropriate, to disseminate scientific guidelines and methods for use by PCNSL researchers. Peer-reviewed publications have resulted from prior meetings including a vision statement for the IPCG; consensus guidelines for clinical trials in the PCNSL patient population; and a summary of the largest series of primary T-cell lymphomas of the nervous system published to date. Treatment-related neurotoxicity in PCNSL patients is the next major prospective IPCG project and will be the subject of the next scientific meeting. Attendance at IPCG meetings includes scientists, neuropsychologists and physicians from multiple specialties involved in every aspect of PCNSL clinical care and research. In addition, distinguished scientists and clinical investigators have been invited to the thematic sessions. Although the group has existed for only 3 years it have fostered international collaboration across multiple disciplines on an unprecedented scale and has had an impact on PCNSL research and clinical care.

描述（由申请人提供）：国际原发性中枢神经系统淋巴瘤协作组 (IPCG) 于 2002 年 6 月在瑞士卢加诺举行的第八届国际恶性淋巴瘤会议上成立，每两年举行一次会议，吸引了多学科和国际成员。 IPCG 的主要目标是促进对原发性中枢神经系统淋巴瘤 (PCNSL) 患者的生物学理解、诊断和治疗。之前会议的主题包括：1）PCNSL 临床试验共识指南； 2）神经系统原发性T细胞淋巴瘤； 3）低度中枢神经系统淋巴瘤。每个主题会议的目标是回顾与每个主题相关的临床前和临床科学；开展针对每个选定主题的多学科合作研究，并在适当时传播供 PCNSL 研究人员使用的科学指南和方法。先前会议产生的经过同行评审的出版物，包括 IPCG 的愿景声明； PCNSL 患者群体临床试验共识指南；以及迄今为止发表的最大系列神经系统原发性 T 细胞淋巴瘤的摘要。 PCNSL 患者治疗相关的神经毒性是下一个主要的前瞻性 IPCG 项目，并将成为下一次科学会议的主题。出席 IPCG 会议的包括涉及 PCNSL 临床护理和研究各个方面的多个专业的科学家、神经心理学家和医生。此外，杰出的科学家和临床研究人员也被邀请参加专题会议。尽管该小组成立仅 3 年，但它已以前所未有的规模促进了跨多个学科的国际合作，并对 PCNSL 研究和临床护理产生了影响。